At the same time, CM patients with high risk scores showed a marked reduction in the expression of almost all immune biomarkers, like BTLA, CD200, NRP1, and so on, except for TNFRSF14 and CD276. This evidence concerns the gene NRP1 and cutaneous mastocytosis.